Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of selinexor versus physician’s choice in previously treated myelofibrosis
2020-003809-60Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of selinexor in myelofibrosis (MF) (2 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Spleen Volume Reduction ≥35%. Started May 2021; status: completed.
02
Drugs
selinexor
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2020-003809-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003809-60.